# Pre-Approval Access to Golimumab Subcutaneous for the Treatment of Stage 3 Type-1 Diabetes Mellitus in Children and Young Adults

> **NCT03945903** · — · NO_LONGER_AVAILABLE · sponsor: **Janssen Research & Development, LLC**

## Conditions studied

- Diabetes Mellitus, Type 1

## Interventions

- **DRUG:** Golimumab

## Key facts

- **NCT ID:** NCT03945903
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** NO_LONGER_AVAILABLE
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2023-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03945903

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03945903, "Pre-Approval Access to Golimumab Subcutaneous for the Treatment of Stage 3 Type-1 Diabetes Mellitus in Children and Young Adults". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT03945903. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*